KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Operating Expenses: 2016-2024

Historic Operating Expenses for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Dec 2024 value amounting to $669.5 million.

  • Amneal Pharmaceuticals' Operating Expenses rose 11.86% to $201.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $716.9 million, marking a year-over-year increase of 11.80%. This contributed to the annual value of $669.5 million for FY2024, which is 12.45% up from last year.
  • According to the latest figures from FY2024, Amneal Pharmaceuticals' Operating Expenses is $669.5 million, which was up 12.45% from $595.4 million recorded in FY2023.
  • Over the past 5 years, Amneal Pharmaceuticals' Operating Expenses peaked at $669.5 million during FY2024, and registered a low of $515.7 million during FY2020.
  • Over the past 3 years, Amneal Pharmaceuticals' median Operating Expenses value was $596.8 million (recorded in 2022), while the average stood at $620.6 million.
  • Its Operating Expenses has fluctuated over the past 5 years, first dropped by 0.24% in 2023, then rose by 12.45% in 2024.
  • Amneal Pharmaceuticals' Operating Expenses (Yearly) stood at $515.7 million in 2020, then increased by 11.60% to $575.5 million in 2021, then rose by 3.71% to $596.8 million in 2022, then fell by 0.24% to $595.4 million in 2023, then increased by 12.45% to $669.5 million in 2024.